Requirement for expert histopathological assessment of ovarian cancer and borderline tumours

The distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following his...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2000-02, Vol.82 (4), p.760-762
Main Authors: SENGUPTA, P. S, SHANKS, J. H, BUCKLEY, C. H, RYDER, W. D. J, DAVIES, J, REYNOLDS, K, SLADE, R. J, KITCHENER, H. C, JAYSON, G. C
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Cell Differentiation
Disease Progression
Female
Genital system. Mammary gland
Humans
Investigative techniques, diagnostic techniques (general aspects)
Medical sciences
Middle Aged
Neoplasm Staging
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques
Recurrence
Short Communication
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaign
ISSN:0007-0920
1532-1827
DOI:10.1054/bjoc.1999.0994